Novo makes a rare disease push

Jennifer E. Engen

The pipelines of some of these therapy areas, such as lysosomal storage diseases, are crowded with gene therapy projects, but Mr Helfgott plays down Novo’s interest in such technology. “We believe gene editing is more attractive for patients than gene therapy, because it’s more durable.” To this end, Novo signed […]